Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
← catalyst calendarNCT07256015 · readout in 320 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
1
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-05 | actual | When the study began enrolling |
| Primary completion | 2027-07-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-05 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriasis
Intervention
- Drug: Deucravacitinib
Primary outcomes
what the primary-completion date above is the date OFThe percentage of participants still receiving deucravacitinib treatment
measured Week 24 and 52
Absolute Psoriasis Area and Severity Index (PASI)
measured Baseline and Weeks 16, 24 and 52
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed